Test Bank for An Introduction to Drugs and the Neuroscience of Behavior, 1st Edition : Prus

This is completed downloadable of Test Bank for An Introduction to Drugs and the Neuroscience of Behavior, 1st Edition : Prus

Product Details:

ISBN 10: 049590726X

ISBN 13: 9780495907268

Author:  Prus, Adam

This up-to-date text provides an introductory overview of the nervous system actions and behavioral effects of the major classes of psychoactive drugs, using pedagogy unique among pharmacology texts to make the topic approachable. Available with InfoTrac Student Collections http://gocengage.com/infotrac.

 

Table of Content:

1. Box 1.1 Instruments Used for Studying Subjective Effects in Humans
2. Study Designs and the Assessment of Psychoactive Drugs
3. Experiments
4. Correlational Studies
5. Validity and the Interpretation of Study Findings
6. Ethical Considerations in Research
7. A Lack of Feasible Alternatives to Animals
8. High Predictive Value for Drug Effects in Humans
9. The Regulation of Animal Research
10. Researchers Consider Many Ethical Issues When Conducting Human Research
11. From Actions to Effects: Therapeutic Drug Development
12. Chapter Summary
13. Key Terms
14. 2 The Nervous System
15. Cells in the Nervous System
16. Neurons
17. Glial Cells
18. The Nervous System
19. The Peripheral Nervous System
20. The Central Nervous System
21. Cerebral Blood Flow and Cerebrospinal Fluid
22. Genes and the Physiological Processes of Cells
23. Box 2.1 Genetically Modified Organisms
24. From Actions to Effects: Advances in Therapeutic Use of CRISPR Genetic Technology
25. Chapter Summary
26. Key Terms
27. 3 Neurotransmission
28. Electrical Events Within a Neuron and the Release of Neurotransmitters
29. Box 3.1 Electrophysiology and Microdialysis
30. Electrical Potentials Along Axons
31. Resting Potential
32. Action Potential
33. Refractory Periods
34. Propagation of Action Potentials Down Axons
35. Neurotransmitters: Signalling Molecules for Neuronal Communication
36. Neurotransmitter Synthesis
37. Neurotransmitter Storage
38. Calcium Influx and Neurotransmitter Release
39. Neurotransmitters Bind to Receptors
40. Termination of Neurotransmission
41. Neurotransmitters and Receptors
42. Postsynaptic and Presynaptic Receptors
43. Neurotransmitter Receptors Are Ionotropic or Metabotropic
44. Types of Neurotransmitters
45. Glutamate and GABA Are the Most Abundant Neurotransmitters
46. Monoamine Neurotransmitters: Dopamine, Norepinephrine, Epinephrine, and Serotonin
47. Acetylcholine
48. Neuropeptides: A Large Class of Neurotransmitters
49. Other Types of Chemical Transmission in the Nervous System
50. Neurotrophins
51. Hormones
52. From Actions to Effects: Probiotics and Mental Health
53. Chapter Summary
54. Key Terms
55. 4 Properties of Drugs
56. Pharmacokinetic Properties of Drugs
57. Absorption
58. Distribution
59. Biotransformation
60. Elimination
61. Pharmacodynamic Properties of Drugs
62. Psychoactive Drugs and Receptors
63. Box 4.1 Radioligand Binding for Measuring Receptor Affinity
64. Box 4.2 The [35S]GTPγS Binding Assay Assesses G-Protein Activation
65. Adaptations to Chronic Drug Use
66. From Actions to Effects: Environmental Neurotoxicology
67. Chapter Summary
68. Key Terms
69. 5 Drugs of Abuse
70. Regulatory Agencies and Drug Classification
71. Clinical Definitions and the Diagnosis of Drug Addiction
72. Theoretical Models and the Features of Drug Addiction
73. Associative Learning Principles Used in Addiction Models
74. Drive, Opponent-Process Theory, and Incentive-Salience Models of Drug Addiction
75. Box 5.1 Self-Administration
76. Disease Model of Drug Addiction
77. Drugs of Abuse and Reward Circuitry
78. Chronic Use of Abused Substances and Changes to Learning and Memory Systems
79. Neurobiology and the Stages of Drug Addiction
80. Mortality and Drug Addiction
81. Psychological and Pharmacological Therapies for Treating Drug Addiction
82. From Actions to Effects: Food Addiction
83. Chapter Summary
84. Key Terms
85. A Final Note About Drug Addiction
86. 6 Psychostimulants
87. Psychostimulants: Herbal Products, Prescription Drugs, and Substances of Abuse
88. Ephedra
89. Amphetamines
90. Methylphenidate
91. Cathinones
92. Cocaine
93. Pharmacokinetics of Psychostimulants
94. Routes and Forms of Psychostimulant Administration
95. Biotransformation of Psychostimulants
96. Elimination of Psychostimulants
97. Psychostimulants and Monoamine Neurotransmitters
98. Amphetamines
99. Methylphenidate and Cathinones
100. Cocaine
101. Cocaine- and Amphetamine-Regulated Transcript
102. Pharmacological Effects of Psychostimulants
103. Physiological Effects
104. Behavioral Effects
105. Subjective Effects
106. Box 6.1 Drug Discrimination
107. Adverse Effects
108. Psychostimulant Drugs Produce Sensitization and Tolerance
109. Psychostimulant Addiction
110. Treatments for Psychostimulant Addiction
111. From Actions to Effects: Psychostimulants as Cognitive Enhancers and Treatments for ADHD
112. Chapter Summary
113. Key Terms
114. 7 Nicotine and Caffeine
115. Nicotine and Tobacco
116. History of Tobacco
117. Pharmacokinetic Properties of Tobacco
118. Tobacco Use and Nicotine Absorption
119. Nicotine Absorption Through Lung and Oral Tissues
120. Distribution and Biotransformation of Nicotine
121. Elimination of Nicotine
122. Nicotine and Nervous System Functioning
123. Nicotine’s Pharmacological Effects
124. Nicotine’s Effects on Cardiovascular Function and Appetite
125. Nicotine Affects Movement and Cognitive Functioning
126. Nicotine’s Positive and Negative Subjective Effects
127. Box 7.1 Conditioned Taste Aversion
128. Adverse Effects of Tobacco Use
129. Nicotine and Psychological Withdrawal
130. Environmental, Genetic, and Receptor Differences Between Light and Heavy Tobacco Users
131. From Actions to Effects: Why People Smoke and How They Quit
132. Caffeine
133. Caffeine and Related Compounds in Plants
134. Caffeine Has an Ancient History
135. Caffeine Absorption, Duration, and Interaction With Other Psychoactive Drugs
136. Caffeine: Antagonist for Adenosine Receptors
137. Caffeine: Mild Psychostimulant Effects
138. Tolerance and Withdrawal During Sustained Caffeine Use
139. From Actions to Effects: Caffeine Habit?
140. Chapter Summary
141. Key Terms
142. 8 Depressants
143. Types of Depressant Substances
144. Depressants and GABA Neurotransmission
145. Barbiturates
146. Barbiturates Serve as Drugs of Abuse
147. Chronic Barbiturate Administration Increases the Risk of Respiratory Depression
148. Abrupt Withdrawal Causes a Barbiturate Abstinence Syndrome
149. Barbiturates Produce Pharmacological Effects Through Facilitating GABA Neurotransmission
150. Benzodiazepines
151. Risks of Benzodiazepine Use
152. Benzodiazepines Facilitate GABA Neurotransmission Through Specific Types of GABAA Receptors
153. Are There Endogenous Benzodiazepines?
154. Z-Drugs
155. Gamma-Hydroxybutyrate (GHB)
156. History of GHB
157. GHB Is a Drug and a Neurotransmitter
158. Pharmacological Actions of GHB
159. Pharmacological Effects of GHB
160. Box 8.1 Electroencephalography
161. GHB Overdose and Risk of Addiction
162. Inhalants
163. History of Inhalants
164. Inhalants: Rapid Absorption and Elimination
165. Pharmacological Actions of Inhalable Solvents
166. Inhalants: Pharmacological Effects and Interference With Oxygen Intake
167. From Actions to Effects: Stimulus Properties of GHB and Toluene
168. Chapter Summary
169. Key Terms
170. 9 Alcohol
171. Alcohol: The Most Commonly Used Depressant Substance
172. Alcohol Production Through Fermentation and Distillation
173. History of Alcohol
174. Pharmacokinetic Factors and Alcohol’s Effects
175. Alcohol and Interactions With Other Drugs
176. Alcohol and Central Nervous System Functioning
177. Alcohol and GABAA Receptors
178. Alcohol and Glutamate Receptors
179. Alcohol and Calcium
180. Alcohol and Serotonin
181. Alcohol and the Endocannabinoid System
182. Pharmacological Effects of Alcohol
183. Types of Drinking and Number of Drinks Consumed
184. Acute Alcohol Consumption and Cardiovascular and Respiratory Functioning
185. Alcohol’s Depressive Effects on Behavioral and Cognitive Functioning
186. Subjective Effects of Alcohol
187. Severe Adverse Effects of High BAC
188. Chronic Alcohol Consumption and Adverse Cardiovascular and CNS Effects
189. Alcohol: Tolerance and Sensitization
190. Alcohol Addiction and Withdrawal
191. Treating Alcohol Addiction
192. From Actions to Effects: Hangover
193. Chapter Summary
194. Key Terms
195. 10 Opioids
196. Opioids: Natural and Synthetic
197. History of Opioid Use
198. Pharmacokinetic Properties and Opioid Abuse
199. Opioid Drugs and the Endogenous Opioid System
200. Opioid Drugs Are Classified by Receptor Actions
201. Opioids and Reward, Pain, and Stress Systems
202. Opioid Rewarding and Analgesic Effects
203. Opioid Receptor Agonists and Rewarding Effects
204. Box 10.1 Conditioned Place Preference
205. Opioid Analgesic Effects
206. Opioid Drugs and Other Therapeutic Effects
207. Opioid Overdose and Respiratory Function
208. Tolerance and Dependence With Chronic Opioid Use
209. From Actions to Effects: Pharmacological Approaches for Treating Opioid Addiction
210. Chapter Summary
211. Key Terms
212. 11 Cannabinoids
213. Historical Use of Cannabis
214. Methods of Cannabis Preparation and Use
215. Cannabinoid Compounds and the Endocannabinoid System
216. Physiological Effects of Cannabinoids
217. Behavioral and Cognitive Effects of Cannabinoids
218. Subjective Effects of Cannabinoids
219. Cannabis Use Disorder
220. Health Risks of Cannabis
221. From Actions to Effects: Medical Use of Cannabinoids
222. Chapter Summary
223. Key Terms
224. 12 Psychedelic Drugs
225. Hallucinogens
226. Origins of LSD and Other Hallucinogens
227. LSD Ingestion and Effects
228. LSD and the Serotonin Neurotransmitter System
229. LSD’s Mild Physiological Effects and Profound Hallucinogenic Effects
230. Hallucinogens and Flashbacks
231. Mixed Stimulant–Psychedelic Drugs
232. MDMA Recreational Use
233. MDMA Metabolism and the Length of Psychedelic Drug Effects
234. MDMA and Serotonin and Dopamine Neurotransmission
235. MDMA’s Psychedelic and Psychostimulant Effects
236. Box 12.1 Social Interaction Tests
237. MDMA’s Adverse Effects
238. MDMA Tolerance and Withdrawal
239. Dissociative Anesthetics
240. Development of Phencyclidine, Ketamine, and Dizocilpine
241. Absorption and Elimination of Phencyclidine
242. Phencyclidine’s Effects on Dopamine and Serotonin Neurotransmission
243. Dissociative Anesthetics and Glutamate Neurotransmission
244. The Anesthetic and Psychedelic Effects of Dissociative Anesthetics
245. Dissociative Anesthetics and Schizophrenia-Like Effects
246. Tolerance and Withdrawal Effects With Dissociative Anesthetics
247. Other Psychedelic Drugs
248. From Actions to Effects: Synesthesia
249. Chapter Summary
250. Key Terms
251. 13 Treatments for Depression and Bipolar Disorder
252. Mental Disorders
253. Depression
254. The Prevalence of Depressive Disorders
255. Neuroimaging Techniques and Functional Differences in Depression
256. Antidepressant Drugs
257. Box 13.1 Animal Behavioral Models for Identifying Antidepressant Drugs
258. Monoamine Oxidase Inhibitors
259. Tricyclic Antidepressant Drugs
260. Selective Serotonin Reuptake Inhibitors (SSRIs)
261. Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)
262. Atypical Antidepressant Drugs
263. Atypical Antidepressant Drugs: Psychedelics
264. Limitations in Antidepressant Drug Effectiveness and Development
265. Length of Response Time
266. Treatment Resistance
267. Placebo Effects in Clinical Studies
268. Depression Severity
269. Pharmacogenetic Factors in Antidepressant Treatment
270. Combination Drug Strategies for Treating Depression
271. Combining Psychotherapy and Pharmacotherapy for Treating Depression
272. Antidepressant Drugs and Monoamine Neurotransmitter Systems
273. Antidepressant Drugs and Serotonin Neurotransmission
274. Antidepressant Drugs and Dopamine Neurotransmission
275. Neuronal Growth Occurs During Antidepressant Treatment
276. Bipolar Disorder
277. Neurobiology of Bipolar Disorder
278. Mood Stabilizers, Anticonvulsants, Antipsychotics, and Antidepressants for Bipolar Disorder
279. Lithium
280. Anticonvulsant Drugs
281. Atypical Antipsychotic Drugs and Antidepressant Drugs
282. From Actions to Effects: Psychedelic Drugs for Treating Depression
283. Chapter Summary
284. Key Terms
285. 14 Treatments for Anxiety Disorders
286. Anxiety Disorders
287. Structures Involved in Fear and Anxiety
288. Box 14.1 Optogenetics
289. Box 14.2 Animal Models for Screening Anxiety Treatments
290. Anxious Feelings, the Amygdala, and the Sympathetic Nervous System
291. Stress and the HPA Axis
292. Anxiolytic Drugs for the Treatment of Anxiety
293. Sedatives for Treating Anxiety
294. Buspirone for Treating Anxiety
295. Anticonvulsant Drugs for Treating Anxiety
296. Beta Blockers for Coping With Anxiety
297. Antidepressant Drugs for the Treatment of Anxiety Disorders
298. MDMA Treatment for Post-Traumatic Stress Disorder
299. From Actions to Effects: How Do Antidepressant Drugs Reduce Anxiety?
300. Chapter Summary
301. Key Terms
302. 15 Antipsychotic Drugs
303. Schizophrenia
304. Box 15.1 Prepulse Inhibition
305. Schizophrenia’s Complex Neurobiological Profile
306. A Brief History of Schizophrenia and Its Treatment
307. Neurotransmission Hypotheses for Schizophrenia
308. Typical and Atypical Antipsychotic Drugs
309. Typical Antipsychotic Drugs: The First Medications for Schizophrenia
310. Atypical Antipsychotic Drugs: First-Line Treatments for Schizophrenia
311. Pharmacological Actions of Atypical Antipsychotic Drugs
312. Box 15.2 Animal Models for Identifying Typical and Atypical Antipsychotic Drugs: Conditioned Avoidance and Catalepsy
313. Third-Generation Antipsychotic Drugs
314. Administration Forms for Antipsychotic Drugs
315. Pharmacogenetics and Antipsychotic Effects
316. Antipsychotic Drugs and Autism
317. From Actions to Effects: Antipsychotic Drug Actions and Neurotransmission in Schizophrenia
318. Chapter Summary
319. Key Terms
320. Glossary
321. References
322. Author Index
323. Subject Index